MedTrace Logo

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease

NCT03550183 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-12-30

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem Cells transplantation in Parkinson's disease.

Conditions

Interventions

BIOLOGICAL

mesenchymal stem cells

Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.

Sponsors & Collaborators

  • Hebei Newtherapy BIo-Pharma technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiqing Chai, Doctor · Hebei Chemical & Pharmaceutical College

  • Ping Gu, Doctor · The First Hospital of Hebei Medical University

  • Hongxu Chen, Master · The First Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-10
Primary Completion
2022-10-10
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03550183 on ClinicalTrials.gov